@article {30, editor = {,}, title = {▾ More ace inhibitors {\textendash} quinapril, perindopril \& ramipril}, volume = {29}, number = {8}, pages = {30--32}, year = {1991}, doi = {10.1136/dtb.29.8.30}, publisher = {British Medical Journal Publishing Group}, abstract = {During 1990 quinapril (Accupro {\textendash} Parke-Davis), perindopril (Coversyl {\textendash} Servier) and ramipril (Tritace {\textendash} Hoechst) joined captopril, enalapril and lisinopril1, 2 as inhibitors of angiotensin-converting enzyme (ACE) for the treatment of hypertension. Of the newer drugs only quinapril is currently licensed for use in heart failure. Claims, such as {\textquoteleft}a unique pharmacokinetic profile{\textquoteright} for quinapril, and of {\textquoteleft}high performance{\textquoteright} for perindopril, and the promotional emphasis on evidence that perindopril reverses hypertensive structural change in arteries, need critical examination.}, issn = {0012-6543}, URL = {https://dtb.bmj.com/content/29/8/30}, eprint = {https://dtb.bmj.com/content/29/8/30.full.pdf}, journal = {Drug and Therapeutics Bulletin} }